Core Viewpoint - The research highlights that chemotherapy can awaken dormant disseminated tumor cells (DTCs) in lung cancer, leading to metastatic recurrence, and proposes a novel combination therapy strategy to inhibit this process [2][4][8]. Group 1: Research Findings - The study established a dormant tumor cell lineage tracing system called DormTracer, confirming that dormant DTCs can be reactivated by chemotherapy, resulting in metastatic recurrence [5][6]. - Chemotherapy drugs, including doxorubicin and cisplatin, enhance the proliferation and lung metastasis of dormant breast cancer cells [4][6]. - The mechanism involves chemotherapy inducing senescence in fibroblasts, which promotes the formation of neutrophil extracellular traps (NETs) that facilitate the proliferation of dormant DTCs [5][6]. Group 2: Proposed Treatment Strategy - The research suggests a new combined treatment strategy using senolytic drugs (dasatinib + quercetin) alongside chemotherapy to inhibit the reactivation of dormant DTCs and suppress tumor metastasis [5][6][8]. - This combination therapy aims to improve treatment outcomes by addressing the adverse effects of chemotherapy on cancer metastasis [8].